today is less invasive and more
routine and effective than its historic counterpart.
Performed percutaneously – via a
catheter through the skin – many cardiac procedures no longer require an open heart surgery approach. Two
such procedures performed this way include replacements and repair of both the mitral and tricuspid valves. Hot
on the trail of aortic valve percutaneous intervention, recent percutaneous mitral and tricuspid valve intervention has yielded significant positive outcomes while filling a void in the field of heart surgery. The exploration of
this technology in a greater patient population is ongoing, but with promising post-op results, the innovation has
significant implications for the future of cardiac care.
Akin to DNA-based
gene therapies, RNA-based therapies are the
newest innovation in
labs nationwide and
have shown immense
with genetic data at the
ribonucleic acid (RNA)
level gives scientists the
ability to intercept a
patient’s genetic abnormality before it is
translated into functioning (or nonfunctioning) proteins. Today, the most popular and successful mechanisms of
RNA therapy include antisense nucleotides and RNA interference. These new therapies are being explored in a
variety of rare genetic diseases such as Huntington’s disease, as well as in cancer and neurologic diseases, with the
hope of treatment by way of alternate genetic data. These new mechanisms of action are opening windows for
progress and innovation in therapeutics.